<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00128739</url>
  </required_header>
  <id_info>
    <org_study_id>25-23/02/01</org_study_id>
    <nct_id>NCT00128739</nct_id>
  </id_info>
  <brief_title>Treatment of Gastro-Intestinal and/or Hepatic Graft Versus Host Disease With Budesonide in Patients Following Peripheral Blood Stem Cell Transplantation</brief_title>
  <official_title>A Phase 3 Study to Evaluate the Place of Budesonide in the Treatment of GVHD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rafa Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dr. Falk Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rafa Laboratories</source>
  <brief_summary>
    <textblock>
      Twenty-four (2 x 12) patients with intestinal graft versus host disease (GVHD) Grades 2, 3 or&#xD;
      4 will be treated with budesonide 3mg three times daily or placebo for 12 weeks. All of the&#xD;
      patients will receive cyclosporine and by mouth (po) prednisone or intravenous (IV)&#xD;
      methylprednisone with a starting dose of 2mg/kg/day (standard anti-GVHD treatment). Doses of&#xD;
      steroids will be decreased by approximately 10% or 10mg per week (depending upon patient's&#xD;
      weight) upon response to therapy, defined as a decrease of volume of diarrhea by 50% per day,&#xD;
      decrease in abdominal pain and no presence of bloody stool. Patients with Grades 3 or 4 will&#xD;
      be withdrawn from the study if there is no response after one week of therapy. Patients with&#xD;
      Grade 2 may continue with no decrease in prednisone dose until response is achieved.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Graft versus host disease (GVHD) is one of the most common complications of bone marrow&#xD;
      transplantation (BMT). Targets of GVHD are the gastro-intestinal tract (GIT) liver and skin,&#xD;
      causing severe diarrhea and mucosal aberration and hepatitis that can cause life threatening&#xD;
      liver failure. As a result of the mucosal aberration and the general immuno-suppression,&#xD;
      caused both by the GVHD process itself and by the anti GVHD therapy, these patients are&#xD;
      highly susceptible for severe, life threatening infections that usually originate from the&#xD;
      GIT. Systemic steroids are the backbone of anti GVHD therapy. However, in GVHD systemic&#xD;
      steroids have to be administered for a prolonged duration and in high doses, thus causing&#xD;
      prolonged immune suppression, and exposing the patients to steroid side effects such as&#xD;
      hypertension, diabetes, cataract formation etc.&#xD;
&#xD;
      Budesonide is a steroid that combines topical anti-inflammatory activity with high first-pass&#xD;
      hepatic extraction. It was shown to be effective in treatment of inflammatory bowel disease&#xD;
      with results slightly less then systemic steroids and fewer steroid-related adverse&#xD;
      reactions. Except for its influence on the gut, budesonide was also shown to benefit&#xD;
      inflammatory hepatic conditions such as primary biliary cirrhosis, liver transplantation and&#xD;
      autoimmune hepatitis. Recently, it has been shown that budesonide is an effective treatment&#xD;
      in acute GIT GVHD. The investigators propose to evaluate the effect of budesonide in GIT and&#xD;
      hepatic GVHD with the following study.&#xD;
&#xD;
      Patients:&#xD;
&#xD;
      Twelve patients after allogenic peripheral blood stem cell transplantation (PBSCT) with grade&#xD;
      &gt;= 2 GIT and/or hepatic GVHD will be prospectively compared to 12 placebo controls.&#xD;
&#xD;
      Inclusion Criteria:&#xD;
&#xD;
        -  Clinical and biopsy proven grade &gt;/= 2 GIT AND/OR hepatic GVHD.&#xD;
&#xD;
      Exclusion Criteria:&#xD;
&#xD;
        -  Preventive antimicrobial treatment (with the exception of Resprim) or somatostatin in&#xD;
           the GIT GVHD patients.&#xD;
&#xD;
        -  Anti-GVHD treatment other then steroids (maximal dose ≤ 2 mg/kg methylprednisolone) and&#xD;
           cyclosporine A or tacrolimus.&#xD;
&#xD;
      Study Protocol:&#xD;
&#xD;
      All patients will be assessed for GVHD scoring (organ and general) according to standard&#xD;
      criteria and tested before inclusion for the following parameters -&#xD;
&#xD;
        -  Colon and/or liver biopsy GVHD staging (including number of crypt abscesses).&#xD;
&#xD;
        -  Liver function tests - blood albumin, AST, ALT, GGTP, Alk Phos, LDH, bilirubin,&#xD;
           coagulation function, cholesterol.&#xD;
&#xD;
        -  Stool - volume and frequency.&#xD;
&#xD;
        -  Radiological - CT scan for mucosal edema, wall thickening and ascites.&#xD;
&#xD;
        -  Kidney function tests - blood creatinine, creatinine clearance.&#xD;
&#xD;
        -  Blood pressure.&#xD;
&#xD;
        -  Fasting blood glucose. If normal - oral glucose tolerance test, glycosylated hemoglobin.&#xD;
&#xD;
        -  Ophthalmologist evaluation for cataract formation and IOP.&#xD;
&#xD;
        -  GIT absorption assessment - xylose absorption.&#xD;
&#xD;
        -  Microbiological - stool culture and stool for CDT, CMV PCR, culture for CMV in blood and&#xD;
           urine.&#xD;
&#xD;
        -  Bone density - by ultrasound.&#xD;
&#xD;
      After inclusion the patients will be treated with budesonide 9 or 15mg per day in divided&#xD;
      doses or placebo. Other anti-GVHD treatment or ursodeoxycholic acid will not be withheld but&#xD;
      tapering off will be tried.&#xD;
&#xD;
      Study parameters:&#xD;
&#xD;
        -  LFT, albumin, PT, cholesterol, renal function, stool volume and frequency, CMV culture&#xD;
           and PCR, clinical GVHD staging - every 2 weeks.&#xD;
&#xD;
        -  Xylose test - every month.&#xD;
&#xD;
        -  Ophthalmologist evaluation, diabetes control and CT scan - every 3 months.&#xD;
&#xD;
        -  GIT and/or liver biopsy for GVHD staging (including number of crypt abscesses) and CMV&#xD;
           PCR, bone density - every 6 months&#xD;
&#xD;
        -  Blood, urine and stool culture during every febrile episode.&#xD;
&#xD;
      Study duration: 14 weeks.&#xD;
&#xD;
      End points:&#xD;
&#xD;
        -  Hospitalizations: due to GVHD and/or due to infections.&#xD;
&#xD;
        -  Overall and GIT or hepatic GVHD staging.&#xD;
&#xD;
        -  Time to response.&#xD;
&#xD;
        -  Maximal daily diarrhea (volume and frequency).&#xD;
&#xD;
        -  Weight.&#xD;
&#xD;
        -  Liver function tests.&#xD;
&#xD;
        -  Cataract formation and IOP.&#xD;
&#xD;
        -  TNF level.&#xD;
&#xD;
        -  Albumin.&#xD;
&#xD;
        -  TPN consumption.&#xD;
&#xD;
        -  Bone density.&#xD;
&#xD;
        -  Hypertension.&#xD;
&#xD;
        -  Diabetes - presence and control.&#xD;
&#xD;
        -  Febrile episodes.&#xD;
&#xD;
        -  Positive cultures.&#xD;
&#xD;
        -  Days of antibiotic therapy.&#xD;
&#xD;
        -  Survival.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2001</start_date>
  <completion_date>August 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>24</enrollment>
  <condition>Graft Vs Host Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with clinical and biopsy proven Grades 2, 3 or 4 intestinal GVHD&#xD;
&#xD;
          -  Patients with a negative stool culture&#xD;
&#xD;
          -  Male or female patients aged between 18 - 70 years&#xD;
&#xD;
          -  Signed written informed consent of the patient&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncertain GVHD diagnosis (other causes of intestinal disease are possible)&#xD;
&#xD;
          -  Severe other disease which may influence the patient prognosis&#xD;
&#xD;
          -  Contraindication to the use of steroids&#xD;
&#xD;
          -  Patient's inability to swallow the study medications&#xD;
&#xD;
          -  Concurrent use of non-steroidal anti-inflammatory drug (NSAID)&#xD;
&#xD;
          -  Known spontaneous or iatrogenic disturbances of thrombocyte aggregation or blood&#xD;
             clotting.&#xD;
&#xD;
          -  Kidney dysfunction with creatinine level higher than 2mg/dl&#xD;
&#xD;
          -  Patients on preventative antimicrobial therapy with the exception of Resprim®&#xD;
             (sulfamethoxazole and trimethoprim)&#xD;
&#xD;
          -  Patients taking somatostatin&#xD;
&#xD;
          -  Patients taking anti-GVHD medication with the exception of steroids (maximum dose of&#xD;
             prednisone or methylprednisolone 2mg/kg/day) and cyclosporine A or tacrolimus&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Insufficient contraception protection&#xD;
&#xD;
          -  Participation in another clinical study within the last 30 days.&#xD;
&#xD;
          -  Mental condition rendering the patient unable to understand the nature or scope and&#xD;
             possible consequences of the study and/or evidence of an uncooperative attitude.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Y Shapira, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Medical Organization</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hadassah Medical Organization,</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>August 2005</verification_date>
  <study_first_submitted>August 9, 2005</study_first_submitted>
  <study_first_submitted_qc>August 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2005</study_first_posted>
  <last_update_submitted>August 26, 2005</last_update_submitted>
  <last_update_submitted_qc>August 26, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2005</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>December 15, 2020</submitted>
    <returned>January 8, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

